Dr People's E75 vaccine program now monitoring her2+ circulating tumor cells 2monitor

[Lani]

response

Looks like it allows patients to have finished immunotherapy

Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29. Links
Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study.

Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.
Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA.
BACKGROUND: Ongoing cancer vaccine trials are limited by the inability of immunologic assays to monitor clinically relevant surrogates of response. Recent advances in the ability to quantify and phenotype circulating tumor cells (CTCs) in breast cancer patients may lead to a role for CTCs in monitoring response to vaccine-based immunotherapy. METHODS: The CellSearch System (Veridex-LLC, Warren, NJ) was used to enumerate total and HER2/neu (+) CTCs in 20 mL of blood from all 16 node-positive (NP) breast cancer patients active in our NP HER2/neu E75 peptide vaccine trial at the initiation of this pilot study. These patients were vaccinated with E75 (1000 mug)/GM-CSF (250 mug) monthly x 6 after completion of multimodality therapy. Mean (+/-SEM) number of CTCs and HER2/neu (+) CTCs were compared in unmatched (n = 16) and matched (n = 9) prevaccination and postvaccination cases. RESULTS: CTCs were detected in 14 of 16 (88%) patients (mean: 3.4 +/- 0.2 CTC/20 mL). After vaccination, a reduction in CTC/20 mL (prevaccination 3.9 +/- 1.5 vs postvaccination 0.7 +/- 0.4, P = .077) and HER2/neu (+) CTC/20 mL (prevaccination 2.8 +/- 1.0 vs postvaccination 0.5 +/- 0.2, P = .048) was demonstrated. A significant delayed-type hypersensitivity (DTH) response suggesting that vaccination was effective in eliciting a peptide-specific immune response was confirmed (22.3 +/- 4.1 vs 3.0 +/- 2.2 [controls] mm, P < .01). All nine patients followed throughout the vaccination series also showed significant reduction in CTCs (4.8 +/- 1.5 vs 0.3 +/- 0.2, P < .01) and HER2/neu (+) CTCs (3.0 +/- 0.9 vs 0.4 +/- 0.2, P = .013). CONCLUSIONS: CTCs are readily demonstrated in posttreatment, clinically disease-free NP breast cancer patients. E75+GM-CSF vaccination appears to reduce the number of CTCs. These data suggest a potential role for this clinically validated CTC assay in assessing response to preventive vaccine-based immunotherapy, and further validation studies are underway.
PMID: 17906897 [PubMed - in process]

[mimiflower07]

hi lani, is there a link to this article? Is this not great news considering they are in phase 3? how long do phase 3 durations last before offered to everyone...just very interesting. Another possible weapon for us.
suzanne

[Lani]

to go there google Entrez PubMed and then put the PMID number (just the number) into the blank rectangle (not good at geek-speak!) and hit return

you should get the full article with information as to whether it is available for free or for a fee.

I am not where I have full internet access so can't give more useful info for now.
Hope this helped!